Malignant Lymphoma in Cats

Lymphoma is the most diagnosed feline cancer. It occurs most frequently in cats already infected with feline leukemia virus (FeLV) or feline immunodeficiency virus (FIV). Cats with FeLV are 62 times as likely to develop malignant lymphoma as those without the virus, and cats with both FeLV and FIV are 77 times more likely to develop it.

Malignant lymphoma in cats tends to affect the T-lymphocytes in younger cats and the B-lymphocytes in older ones, though cats of any age can get either variant of the disease. Cats, like dogs, can develop mediastinal, multicentric, gastrointestinal and extranodal growths, but in cats, gastrointestinal growths are most likely.

Classification

Gastrointestinal lymphoma such as that experienced in cats can be classified as low or high grade. Low grade lymphomas include lymphocytic and small cell lymphoma, while high grade variants are lymphoblastic, immunoblastic, and large cell lymphoma. Low grade only occurs in the small intestine, while high grade commonly affects the stomach.

Signs and Symptoms

Malignant lymphoma in cats is likely to produce visibly severe symptoms (Compare this to dogs, which may only show enlargement of the lymph nodes). The location of symptoms will often indicate the areas of cancerous involvement, with the following types determining the most common signs:

  • Gastrointestinal - Weight loss, roughened coat, and loss of appetite
  • Mediastinal - Respiratory distress caused by a buildup of fluid within the thoracic cavity
  • Renal/Kidneys - Enlargement of kidneys on both sides, eventually leading to renal failure
  • Ocular - Anterior uveitis (inflammation of the interior of the eye) and, eventually, blindness

In addition to these symptoms, cats with FeLV will also often present with anemia-related paleness of the mucus membranes. It is important to test for FeLV and FIV in cats suspected of having lymphoma, and to biopsy the bowels to eliminate inflammatory bowel disease as a cause of symptoms.

Treatment and Prognosis

The standard treatment for feline lymphoma is chemotherapy, though gastrointestinal lymphoma can sometimes be successfully treated with prednisolone and high dose pulse chlorambucil. White blood cell counts must be measured carefully and treatment discontinued if the immune system is too severely depressed.

About 75 percent of cats experience remission of the cancer as a result of chemotherapy, although, like dogs, this is almost invariably followed by a relapse of the disease, after which further remission is unlikely. Untreated, the lymphoma can cause death within four to six weeks, and the average survival after beginning treatment is six months. In about a third of cases, the cat may survive over two years, and a very small percentage of cats are completely cured.

Cats experience fewer side effects from chemotherapy than both dogs and humans, with only five percent showing severe reactions. Cats will not typically lose their fur, though they might lose whiskers. Vomiting, lowered white blood cell count, loss of appetite and fatigue are the most common side effects, but these are typically easy to resolve, leading to an improved quality of life during treatment.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap